HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock.

A number of other research analysts have also weighed in on LCTX. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday. Maxim Group decreased their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX opened at $0.53 on Tuesday. The business’s fifty day moving average is $0.60. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61. The firm has a market capitalization of $117.04 million, a PE ratio of -4.43 and a beta of 1.21.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fort Sheridan Advisors LLC raised its holdings in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after acquiring an additional 23,000 shares during the period. Atria Wealth Solutions Inc. purchased a new position in Lineage Cell Therapeutics during the fourth quarter worth about $29,000. HighTower Advisors LLC raised its stake in Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after purchasing an additional 19,100 shares during the period. SG Americas Securities LLC boosted its holdings in Lineage Cell Therapeutics by 35.5% in the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after buying an additional 65,864 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.